NO20064982L - 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav - Google Patents

1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav

Info

Publication number: NO20064982L
Authority: NO; Norway
Prior art keywords: oxadiazole; ones; delta modulators; ppar delta; compounds
Prior art date: 2004-04-01

Application number

NO20064982A

Other languages

English (en)

Norwegian (no)

Inventor

Stefanie Keil

Jean Merrill

Karen Chandross

Jochen Goerlitzer

Wolfgang Wendler

Daniel G Mcgarry

Patrick Bernardelli

Original Assignee

Aventis Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-01

Filing date

2006-10-31

Publication date

2006-10-31

2006-10-31 Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc

2006-10-31 Publication of NO20064982L publication Critical patent/NO20064982L/no

Links

WTSXVIMLKCKWIW-UHFFFAOYSA-N 3h-1,3,4-oxadiazol-2-one Chemical class O=C1NN=CO1 WTSXVIMLKCKWIW-UHFFFAOYSA-N 0.000 title abstract 2
108010015181 PPAR delta Proteins 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 abstract 3
208000016192 Demyelinating disease Diseases 0.000 abstract 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
230000004129 fatty acid metabolism Effects 0.000 abstract 1
239000008103 glucose Substances 0.000 abstract 1
239000008177 pharmaceutical agent Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Inks, Pencil-Leads, Or Crayons (AREA)

NO20064982A 2004-04-01 2006-10-31 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav NO20064982L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US55841904P	2004-04-01	2004-04-01
PCT/US2005/010854 WO2005097762A2 (en)	2004-04-01	2005-03-30	1,3,4-oxadiazol-2-ones as ppar delta modulators

Publications (1)

Publication Number	Publication Date
NO20064982L true NO20064982L (no)	2006-10-31

Family

ID=34972933

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20064982A NO20064982L (no)	2004-04-01	2006-10-31	1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav

Country Status (17)

Country	Link
US (1)	US7576109B2 (de)
EP (1)	EP1735303B1 (de)
JP (1)	JP4813460B2 (de)
KR (1)	KR20060135854A (de)
CN (1)	CN100516065C (de)
AT (1)	ATE507226T1 (de)
AU (1)	AU2005230837A1 (de)
BR (1)	BRPI0509468A (de)
CA (1)	CA2561738A1 (de)
DE (1)	DE602005027677D1 (de)
IL (1)	IL178167A0 (de)
MA (1)	MA28562B1 (de)
NO (1)	NO20064982L (de)
NZ (1)	NZ550857A (de)
RU (1)	RU2375358C2 (de)
WO (1)	WO2005097762A2 (de)
ZA (1)	ZA200607851B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2365589C2 (ru) *	2004-04-01	2009-08-27	Авентис Фармасьютикалз Инк.	1,3,4-оксадиазол-2-оны в качестве модуляторов ppar-дельта, фармацевтические композиции на их основе и способ лечения
US7968723B2 (en)	2004-05-05	2011-06-28	High Point Pharmaceuticals, Llc	Compounds, their preparation and use
EP1745014B1 (de)	2004-05-05	2011-07-06	High Point Pharmaceuticals, LLC	Neue verbindungen, deren herstellung und verwendung
AU2006265172B2 (en)	2005-06-30	2011-09-15	Vtv Therapeutics Llc	Phenoxy acetic acids as PPAR delta activators
JP2009509988A (ja)	2005-09-29	2009-03-12	サノフィ−アベンティス	フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
PT1931660E (pt)	2005-09-29	2012-10-30	Sanofi Sa	Derivados de fenil-[1,2,4]-oxadiazol-5-ona com grupo fenilo, processos para a sua preparação e sua utilização como fármacos
NZ568488A (en)	2005-12-22	2011-07-29	High Point Pharmaceuticals Llc	Phenoxy acetic acids as PPAR delta activators
CA2645719A1 (en)	2006-03-09	2007-09-13	High Point Pharmaceuticals, Llc	Compounds that modulate ppar activity, their preparation and use
US20080004281A1 (en) *	2006-06-28	2008-01-03	Kalypsys, Inc.	Methods for the modulation of crp by the selective modulation of ppar delta
US20120020931A1 (en) *	2010-06-02	2012-01-26	Rutgers, The State University Of New Jersey	Therapeutic encapsulated embryonic stem cells and mesenchymal stromal cells
ES2811087T3 (es)	2013-09-09	2021-03-10	Vtv Therapeutics Llc	Uso de agonistas de PPAR-delta para tratar la atrofia muscular
WO2021092279A1 (en) *	2019-11-06	2021-05-14	Board Of Regents, The University Of Texas System	Methods for the treatment of dysmyelinating/demyelinating diseases
WO2023147309A1 (en)	2022-01-25	2023-08-03	Reneo Pharmaceuticals, Inc.	Use of ppar-delta agonists in the treatment of disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4826990A (en) *	1987-09-30	1989-05-02	American Home Products Corporation	2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US5103014A (en) *	1987-09-30	1992-04-07	American Home Products Corporation	Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives
US4895953A (en) *	1987-09-30	1990-01-23	American Home Products Corporation	2-Aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US5641796A (en) *	1994-11-01	1997-06-24	Eli Lilly And Company	Oral hypoglycemic agents
CA2377246A1 (en) *	1999-06-18	2000-12-28	Ranjit C. Desai	Arylthiazolidinedione and aryloxazolidinedione derivatives
GB9914977D0 (en) *	1999-06-25	1999-08-25	Glaxo Group Ltd	Chemical compounds
ATE260912T1 (de) *	1999-09-08	2004-03-15	Glaxo Group Ltd	Oxazol ppar antagonisten
JP4145230B2 (ja) *	2002-11-01	2008-09-03	武田薬品工業株式会社	神経障害の予防・治療剤
TW200505441A (en) *	2003-03-24	2005-02-16	Hoffmann La Roche	Non-nucleoside reverse transcriptase inhibitorsⅠ
RU2365589C2 (ru) *	2004-04-01	2009-08-27	Авентис Фармасьютикалз Инк.	1,3,4-оксадиазол-2-оны в качестве модуляторов ppar-дельта, фармацевтические композиции на их основе и способ лечения

2005
- 2005-03-30 DE DE602005027677T patent/DE602005027677D1/de not_active Expired - Lifetime
- 2005-03-30 NZ NZ550857A patent/NZ550857A/en unknown
- 2005-03-30 KR KR1020067020431A patent/KR20060135854A/ko not_active Ceased
- 2005-03-30 CA CA002561738A patent/CA2561738A1/en not_active Abandoned
- 2005-03-30 CN CN200580010054.5A patent/CN100516065C/zh not_active Expired - Fee Related
- 2005-03-30 EP EP05766888A patent/EP1735303B1/de not_active Expired - Lifetime
- 2005-03-30 JP JP2007506540A patent/JP4813460B2/ja not_active Expired - Fee Related
- 2005-03-30 BR BRPI0509468-2A patent/BRPI0509468A/pt not_active IP Right Cessation
- 2005-03-30 AT AT05766888T patent/ATE507226T1/de not_active IP Right Cessation
- 2005-03-30 AU AU2005230837A patent/AU2005230837A1/en not_active Abandoned
- 2005-03-30 RU RU2006138485/04A patent/RU2375358C2/ru not_active IP Right Cessation
- 2005-03-30 WO PCT/US2005/010854 patent/WO2005097762A2/en not_active Ceased
2006
- 2006-09-18 IL IL178167A patent/IL178167A0/en unknown
- 2006-09-19 ZA ZA200607851A patent/ZA200607851B/en unknown
- 2006-09-26 US US11/535,227 patent/US7576109B2/en not_active Expired - Fee Related
- 2006-10-31 NO NO20064982A patent/NO20064982L/no not_active Application Discontinuation
- 2006-10-31 MA MA29428A patent/MA28562B1/fr unknown

Also Published As

Publication number	Publication date
US20070060626A1 (en)	2007-03-15
WO2005097762A2 (en)	2005-10-20
CA2561738A1 (en)	2005-10-20
JP2007531763A (ja)	2007-11-08
CN100516065C (zh)	2009-07-22
DE602005027677D1 (de)	2011-06-09
NZ550857A (en)	2009-12-24
EP1735303B1 (de)	2011-04-27
IL178167A0 (en)	2006-12-31
RU2375358C2 (ru)	2009-12-10
AU2005230837A1 (en)	2005-10-20
BRPI0509468A (pt)	2007-09-11
JP4813460B2 (ja)	2011-11-09
CN1938305A (zh)	2007-03-28
EP1735303A2 (de)	2006-12-27
ATE507226T1 (de)	2011-05-15
KR20060135854A (ko)	2006-12-29
WO2005097762A3 (en)	2005-12-15
ZA200607851B (en)	2008-06-25
US7576109B2 (en)	2009-08-18
RU2006138485A (ru)	2008-05-10
MA28562B1 (fr)	2007-04-03

Legal Events

Date	Code	Title	Description
2011-10-24	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
SG170101A1 (en)	2011-04-29	2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
TW200728305A (en)	2007-08-01	Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
DK1689721T3 (da)	2010-09-20	Aminopyrazolderivater som GSK-3-ihibitorer
MX2008013836A (es)	2008-11-10	Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
EP1562897A4 (de)	2007-06-27	Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
MXPA03011484A (es)	2004-03-18	Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
NZ539841A (en)	2007-11-30	Hydroxyethylamine derivatives for the treatment of alzheimer's disease
EP1689713A4 (de)	2009-02-18	Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EA201170705A1 (ru)	2011-12-30	Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1
CY1107956T1 (el)	2013-03-13	Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
NO20071042L (no)	2007-04-19	5-substituerte 2-fenylaminobenzamider som MEK-inhibitorer
WO2008030412A3 (en)	2008-11-20	Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
WO2006044497A3 (en)	2006-09-08	Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
NO20082496L (no)	2008-07-24	Pyrazinderivater
EP2091328A4 (de)	2010-11-03	Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
DK1641454T3 (da)	2009-02-09	Pyrazolo[3,4-B]pyridin-6-oner som GSK-3-hæmmere
SG151336A1 (en)	2009-04-30	1,3,4-oxadiazol-2-ones as ppar delta
NO20064982L (no)	2006-10-31	1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav
EP1817312A4 (de)	2009-11-04	Makrozyklische aminiopyridyl-beta-sekretase-hemmer zur behandlung von morbus alzheimer
DE602006009556D1 (de)	2009-11-12	Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
DE602005014629D1 (de)	2009-07-09	Pyrazolphenylderivate als ppar-aktivatoren